YouTube Transcript:
RUMA Agriculture Targets Task Force 2 FINAL Report and VARSS Report launch 2025

Skip watching entire videos - get the full transcript, search for keywords, and copy with one click.

Video Transcript

Video Summary

Summary

Core Theme

This webinar discusses the release of two key reports on antibiotic use and antimicrobial resistance (AMR) in UK food-producing animals: the Veterinary Medicines Directorate's (VMD) antibiotic use and surveillance data for 2024, and the RUMA Targets Task Force 2 (TTF2) report summarizing the fifth year of progress on antibiotic use targets. Both reports highlight significant progress in reducing antibiotic use and managing AMR, while also acknowledging ongoing challenges and the need for continued efforts.

Mind Map

Click to expand

Click to explore the full interactive mind map • Zoom, pan, and navigate

Good morning everyone. Um my name is

Gwen Ree. I am British Veterary

Association junior vice president and

lecturer in veterary science abberis university

university

and I am absolutely delighted to be your

chair today in this webinar where we are

discussing the launch of two very

important reports both of which were

released yesterday.

So the first is the veterary medicine's

directorates's release of antibiotic use

and surveillance data for food producing

animals in 2024. And the second report

that we're going to look at is the rumor

targets task force report which

summarizes the fifth and final year of

progress in this cycle of antibiotic use

targets identified by the UK livestock

industries targets task force 2. So the

third cycle of targets task force

targets will be released this time next

week. So tune in next week for the next

cycle of targets. Um but the reports

that we are going to be looking at

today, they give us the annual update on

how the you the UK's livestock sectors

have performed on antibiotic use over

2024 and they give us a bit of an

insight into the AMR surveillance work

that's been going on as well. So I'm

delighted to introduce our presenters

today. First up, we're going to have

Kitty Healey, head of surveillance

division and head of AMR at the veterary

medicine's directorate. And we also have

Katherine McLolin, chair of Rumor

Agriculture here. So, welcome to you both.

both.

After the presentations, I will be

putting some questions to both

presenters and if there is time, we may

be able to answer some questions from

attendees as well. So, please feel free

to pause any questions in the Q&A

function. They'll come up. I'll be able

to see those questions and hopefully

we'll have some time to address some of

those as well.

So just before we get started, I wanted

to take a moment to thank everyone for

their contributions to the development

of both reports. Collecting all this

information and cohesively presenting it

is no small job and it's involved many

many stakeholders from across all

sectors and industries as well as BMD

and rumor agriculture. It's taken a lot

of hard work, time, and effort. And we

are really, really grateful for all of

that work.

Little bit of housekeeping as well

before we start just to help today's

session run smoothly. Just want to go

over a few practical elements before we

get started. So hopefully all of your

cameras and microphones should be off

and muted. If not, please can you do so

just so that we keep everything nice and

smooth. You can say you can see that

we're running today's meeting on Teams.

So both of today's speakers will shortly

be sharing their screens to present

their report updates. If you do have any

questions, please pause them in the Q&A

function as I said and as chair if

there's time I'll help with coordinating

these questions to the speakers but that

will be after both presentations have

been completed. So the discussion will

be at the end and not after each

presentation and that's just so that we

don't disrupt the flow really of the

presentation. We may not have time to

answer all questions today. Um, but if

you do have any questions that you feel

haven't been answered or after the

webinar has finished, please contact the

comm's team either at the VMD or at

rumor. The email contexts of which will

be shared in the Q&A function before the

end of the webinar. Okay, so that's all

of the housekeeping and the intro. So

I'm now going to hand over to Kitty to

share details about the VAS report. Over

to you Kitty.

>> Thanks very much Gwen. Right, let me

which I know I have right here because I

literally just um made sure that I could

share them. So, if you would bearing

everybody take a sip of your cups of tea.

tea.

>> It's always the most painful bit with

Teams, isn't it? Getting the um getting

>> Absolutely. Trying trying to share my

slides with you rather than my whole

desktop. So, um >> Yes.

>> Yes.

>> we will be we will be there in just a

moment. Right. Okay. Hold on a second.

Right, I think I have it.

>> Something's coming up. Yes. >> Yeah.

>> Yeah.

>> Just need it in slideshow mode.

There we are. >> Okay.

>> Okay.

>> Is that working on your side, Gwen?

Yep, I can see that perfectly.

>> Brilliant. Okay, super. Thank you very

much again and um apologies for the um

for the classic technical um hitches at

the beginning. Um so, thank thank you

Gwen um for the introduction. Um thank

you all for um for coming along. Um, and

I'd like to also um repeat Gwen's thanks

to um everybody who's contributed to um

from our side from to the UK vase

report, the veterary antibiotic

resistance and sales surveillance report

2024 um containing data from 2024

published um this year in 25. Um it's a

huge um effort, huge amount of work in

the VMD and in many um parts of um

government and the devolved

administration. So thank you to all of

you. Um, and I'm delighted to be sharing

the um the highlights from it um today.

Um, so I'm going to do what I usually do

um in um in these presentations. Um I'm

going to take you through the different

sections of the VARS report. Um and um

that means that we'll do it in the same

order as it is in the report and we'll

start with sales, antibiotic sales and

antibiotic usage data. Um but this time

um I'm starting with a slightly

different slide from normal because in

this report we have introduced a new

metric. Um and I'm going to spend a

couple of slides just talking you

through that because um it's important

to understand what's different and

what's the same because this changes the

numbers but it doesn't change the

underlying um source of of of the data.

So we are are changing from what we used

to um have as a milligrams per kilogram

um metric which is based on the old SVAC

European uh metric um which we are now

going to be calling the MIGs per PCU or

MIG per population correction unit um

metric. So when you hear us talking

about MIG per PCU, we're talking about

the old one which has been in previous

FAS report. When we talk about MIG

perig, we're now going to be talking

about the one that we're introducing in

this um report today. Um and this new

metric is based on a new metric that's

being rolled out um for European data.

And we're doing this for several

reasons. Um we're doing this because um

it better represents the UK data um uh

and animal populations just as it does

um in the EU. Um it has additional

categories of of species um for cattle

laying hens and ducks for example. And

so we we're able to capture um some data

that we weren't able to capture before.

Um it of course allows regional

harmonization of um of monitoring data

which is something which is important.

It's important for understanding not

just um what's going on in the UK but

what's going on contextually in our in

our close neighbors. Um and also um with

a slightly more global look, it rep it's

it's closer, it's not the same as but

it's closer to the um the methodology

used by the World Organization for

Animal Health's um system uh in Animuse,

their database. Um so how is it

different? Well, we're still dividing

the weight of antibiotics sold for the

sales data or the weight of antibiotics

used in the usage data. So this metric

applies to sales and usage data. Um but

the the weights as well as some of the

categories having changed the weights

that are being used for calculating um

the metrics. So for um for dividing um

the the the uh total um antibiotic

weight by have have changed as well and

by and large um those weights are um

increasing. So um that you end up in the

end with a lower overall metric. So you

will see that the instead where we where

we had a higher metric. In fact, let me

move to my um actually no, I'll wait for

a second before I move to my next slide.

But the takehome is that while the

national level um and the species sector

um level results will look lower,

they're not lower because the

methodology has changed. So that's

that's the big thing to to to get over.

Um and if you want to see whether they

there is actually a drop in the usage

then you need to look at the trend data

and we have applied the new methodology

to the trends going back. So all the

data that you look at in the vase report

you'll be able to see um the trend data

with the the new metric. Um you'll see

in a couple of slides we've also done

some comparisons with the old metric for

the sales data so that you can actually

see that visually.

So I said that the weights are different

and this slide is really just to give

you um an idea so that you can see for

yourselves. um the weights have changed

um in the different they're not the same

change in in weight for each um species

or each sector. So you can see here for

pigs we've gone um from using 65 kilos

um as the weight um uh the weight per

animal which is the weight estimated

weight at time of treatment to 120 kilos

which is the weight of the animals um at

staughter and you can see that that

results in a 42% reduction in the end

metric. So, and you can see that that

this this same trend is is seen for

other species as well. Um, and all that

this is showing you um at the at the

bottom here is um where we're also um

refine we we've got um some refinement

to the um to the categories of of

species that we're um including. So, I'm

going to leave it there because I don't

want to over complicate it, but the

bottom line is represents the UK

situation better, harmonizes with

Europe, better harmonized with the um

the global situation and look at the

trend data because the data that goes

into this is the same and we just need

to gradually get used to the fact that

the actual number coming out of it is

going to look a little bit unfamiliar

until we until we get used to it.

Now, I said that I was going to show you

some comparative data. And so, here is

our headline sales um slide. So, this

shows you the trends for the total sales

of antibiotics. And just as a reminder

for those of you who haven't um spent

your heads in this in all of this data

for the last few weeks, um total sales

of antibiotics, this is the um this

represents the total weight of

antibiotics that are sold at a

pharmaceutical company level. So, this

is um whole of the UK data. Um and when

we've um uh got the the the bar chart is

is showing um that um for food producing animals.

animals.

And you can see here we've got the old

metric. We've tried to color code it.

The old metric is excuse me the old

metric is the the blue bars and the new

metric is represented by the pink or red

bars. And you can see the numbers there

for the last couple of years um at the

top in the table again colorcoded. Um

and so you can see what I was saying

overall it's lower in terms of the the

outcome of the metric but when we look

at the trends the trends um follow the

same pattern. Of course they do. It's

the same data that's going into it. Um

now if we look at 2024 compared to 2023

um what we see is essentially no change.

I mean there's a very very tiny change

um uh very tiny reduction in the MIGs

per kig um that you can see there with

the population corrected um trends um

but in fact if we look at some other um

areas of data which we can't reflect in

in this um graph um on imported data

that's actually showing a slight trend

to increasing compared with previous

years. So in fact um that pretty much

takes out the the reduction. So we're

we're looking um at overall um a steady

picture for antibiotic sales at the

national level. Um of course there's

differences in different sectors and

I'll come on to that with the usage. Um,

now some of you who follow the data

really closely might um be surprised to

see a 57% reduction since 20 um 20 sorry

since 2014 since we've previously um had

a um a 59 reduction 59% reduction and

that is due to um a correction that we

became an error in the data which goes

back many years which we became aware

of. It's not it's it's in horses. So

although we include it in the food

producing animals, it's not in a farmed

animal. Um, so that has just made a

slight adjustment to the data going all

the way back, but it's something it's a

correction. It changes the figure, but

it doesn't change um it doesn't change

the trend.

Um, and the last point to make on this

slide is that we have the the total

tonnage um of antibiotics sold in the

UK, not corrected for population um the

populations of animals in which um it's

used running along the bottom there. You

can see there's been a a slight drop in

the last year but um when we correct

that for populations um as you can see

from the bars then there's no

significant change. Um we again they see

If we move on then to look at the sales

of the um highest priority critically

important antibiotics.

So these are the ones the um which are

highest priority critically important

for use in um human medicine. So we take

extra special um care with those in our

stewardship in um in animal health. You

can see here that these remain really

really low at 0.6 milligrams per

kilogram. Again new metric applied to

these um and that's less than half a

percent um is point4% of the total

antibiotic sales and food producing

animals. So essentially no change since

2023 last year um and maintaining that

really big um 84% reduction since um

2014. Um so this is overall a very

encouraging picture um on the ongoing um

commitment to the the stewardship of

So I'm going to move on to um use of um

antibiotics and antibiotic usage by by

sector. So where we're reporting um uh

usage at a a vet practice or a farm

level. Now we haven't done the

comparison here with the old metric and

the new metric because the slides will

just get too busy. Um but you can see

that if you're interested in the vase

report and and supplementary material

itself. So what you're seeing here from

now on is entirely new metric. So

reminder focus on the trends. Um

anything that says mix pig is new

metric. Um so these are figures taken

from the vase highlights report. Now you

can um do do go and have a look at the

vase highlights report itself.

I'll talk you through these um briefly.

Um so what you're what you're looking at

here is um uh we've got another slide

with the the other um four sectors that

report um uh against antibiotic usage.

We've got the sectors um down on the

left hand side um with their little

infographics there. Then we've got the

um the boxes um with the dots in them

and each then so that's the uncorrected

tonnage. So each dot represents one ton

so that you can see just for the for the

sector what tonnage of of antibiotics is

being used in that sector.

And that's how we've ordered the um the

sectors on these slides. Then you can

see um the mix perig use in 2024, the

change since 2023, and then the really

um the one I I guess I' I've been

encouraging you to focus on, which is

the the trends over time. Um which is

the um the bit on the on the right hand

end. Um and then you have the the

percentage change um that you see over

that of that trend line. So you can see

um in pigs we've had um a trend which

has been um a really really good

reduction and then holding pretty pretty

steady um although we have seen a little

bit of an increase um in the last um

year um which follows on from a a

similar small increase the year before.

So, a couple of years of of increases,

but at a relatively um modest level. Um

um and this does I I mentioned that um

the sales data didn't include imported

um imported antibiotics, but of course

the usage data does include these

imported antibiotics and so um they're

not they're not getting out of it with

the um uh with the usage data

on the um side of the broiler. Again,

you can see this is um significant

reductions a number of years ago and

being held low um staying low and um and

a and a slight reduction um since last

year showing up in um in in the current

vase report.

Then we go to game birds and and and

actually for game birds and for laying

hens, I'll draw your attention to the

fact that we have a a dotted line around

the um uh around the the the 2024 and

the change in the 2023 um boxes. Um

that's because neither of these sectors

uses the mix perig metric. So game birds

um don't correct for population and what

we have is tons um of use here. So um

and you can see that there's been a bit

of a an up and down picture

um for usage in um in game birds and

we've seen um an increase in the last

year following on from an increase the

year before. Now of course this does um

uh the usage is impacted by changes in

the gamebird population because it's not

corrected for population changes. But

the change in the game bird population

doesn't completely account for the

increase um in um antibiotic use over um

the last um year. And so this is a this

is a real um increase

um despite being a reduction since um

they started um recording as it is for

for um all of these sectors on the on

the slide. And then lastly with the

laying hens now um again laying hens as

I just mentioned don't use the mix per

kick metric. Um now that in in in their

case is because they have um extremely

good and detailed um data and instead um

use um a bird a daily bird doses um per

100 bird days at risk um metric so that

that accounts accounts um better for the

antibiotic use that they um have in that

sector. And you can see here um

essentially that they have um they start

they started low they've they've got

even lower and although there's a a

slight increase in the last year

essentially this is from a low level to

Right. So then um if we move on to the

um the second um uh slide for for usage

data um looking at turkey, salmon, trout

and ducks. Essentially um I won't spend

as long on this slide. All of these are

relatively low uses in terms of total

tonnage as you can see here with the

dots. Um and low uses in terms of um uh

in terms of milligrams per kilogram. Um

with um turkeys, we've seen a very

slight increase in the last year, but

very low um uh keeping at low levels

overall. Um salmon and trout um both

fish sectors have have seen um

reductions in the last year and and

salmon to um an all-time low. Um which

is um which is uh great to see. um I

hesitate simply because of course it's

not a race to the bottom but it's also

great to see what can be achieved um in

reducing the the need to use

antibiotics. Um and then in ducks um you

can see there we've got a very very

slight uptick but that's just a you know

from again one of these from a from a

very low level to increasing to still a

very low level. So we're not we're not

seeing any concerns there.

So then um on usage let's just turn our

attention to the highest priority

critically important antibiotics here.

So what we really see here so again

we've ordered these in terms of total

tonnage uh well kilograms used total

weight used um and we see that um the um

the highest user in terms of um in terms

of the weight of HPCAS used um is still

the game birds which is um it it's

slightly concerning that since they are

a relatively small sector they are they

are the highest um using sector by

volume but um nevertheless we we

definitely welcome the sector's renewed

efforts to make sure that these um these

antibiotics and I think it's um

ferocinolones that are that make up the

HPCIA use in the sector um to make sure

that they are used as a last resort with

with a good reason and and we do look

forward to these changes um being uh

reflected in future usage data results.

Um in trout you can see that um the

trend is for it to be going down. Um the

only um HPCIA used in trout is the

quinolone oxyenic acid. um there are not

very many antibiotics authorized uh for

use in in in trout as it is and in fact

oxlinic acid is imported um as the only

effective uh treatment for entic red

mouth. So that's that's the rationale

behind um the the trout use. Um and then

really I think all I'll say about the

pigs laying hens in meat poultry is um

just it shows the the results of the

stewardship efforts here in um in

keeping HPCIA use in these in these big

sectors keeping HPCA use low um which is excellent.

excellent.

Right. Okay. Um now you'll have noticed

that we still unfortunately don't have

ruminant data in our usage data. Um

although there's been lots going on and

and huge um efforts to um to um improve

the uh level of of usage data from the

um from the different ruminance sectors.

So this shows you an update of um of

where we're up to um at this point. So

we have included um dairy cattle and

sheep in the VA report the data from

excuse me dairy cattle and sheep um in

the VA report but we've included them as

as as these figures here because it's

not possible um on the basis of the

coverage that we have to um to assess um

trend data and we haven't included the

beef sector because of the large variety

of of the beef farm types within the UK

which means that um it's it's even

harder to um to to tell whether or not

that's um the data that is collected is

is indicative of the national um

picture. But um we're absolutely looking

forward to um to more data coming in and

and certainly um even in the last year

the dairy sector um uh has increased the

coverage by by 9%. So um uh so um

hopefully we'll have even more to report

in the next report.

But what we do have for um for dairy is

um sales data on intramory. And of

course although these are sales data

because they are intrammemory products

for dairy cows they are reflective of

use in this sector. Um and what you can

see here is um decreasing trends in dry

cow tubes and lactating um cow tubes. Um

although we are seeing that the rate of

reduction is somewhat slower for

lactating cow tubes. Um uh sorry for for

dry cow tubes is slightly slower than

for lactating cow tubes. So the dry cow

tubes being the um the red line and the

lactating tubes um being the um the blue

line. Um although we know that there is

absolutely a drive within the industry

to to focus away from um blanket dry cow

therapy. So um hopefully we'll be um

continuing to see that reduction in um

companion animals. Right. So um with

companion animals um cats and dogs we

don't have usage data per se but in

order to um to get trends we look at um

we look at the sales data and we we

apply an approach called stratification.

So I'm not going to go into detail here

because it will take too long. Um but um

the details are all in the vase report

but it does um help us to get an idea of

um of the of the trends for overall use

um and the trends for HPCIA use. So

overall use on the left hand side and

HPCIA use um on the right hand side. Um,

you can see that still the HPCIA I mean

I think that the the the biggest

take-home message here is that you can

still see that the HPCIA use in cats is

is significantly um higher than than we

would like significantly higher than

dogs and higher than we would like. Um,

but we're very much supportive of the

veterary stakeholder groups who are

working um to improve stewardship um in

companion animals. We're seeing that

things are are gradually coming down

which is which definitely shows that

there is um there there are changes of

foot um and many of you may know that um

there were targets announced um last

week I believe and one of those targets

is a commitment to reduce the use of

HPCIA 50%. So again we look forward to

um to seeing those um uh those efforts

coming through in the um in the data in

in future years.

And then the um last sector I'm going to

cover is um horses. Um and we're really

delighted to include in the VA report

for the first time this year, a section

on antibiotic usage data from horses. Um

uh the progress in this sector has

really been driven by um the uh British

Aquin Veterary Association Beaver um and

their work with the monitor me scheme um

and their work with um uh PRA using

practice management software um to

extract the data um and through doing

that they've um they've managed to cover

25% of the um UK equin population. So

that's a a wonderful start and we are

looking forward to seeing how um this

expands um in future years so that we

can start to get trend data and and

hopefully higher coverage.

And on the note of coverage um this is

just a sort of a representation of um

the level of coverage the the the extent

of the UK population that we're seeing

um uh covered um in terms of antibiotic

usage data. Um, I

don't think I will dwell on this slide

because I think essentially it covers um

it summarizes things that I've been

saying as I've been talking throughout.

Um, but um yeah, but it it helps to

present this in a in a visual way.

Right. So, let's move on then um to the

um resistance data. And so, um I'm going

to start the resistance data looking at

the harmonized monitoring. So the

harmonized monitoring is um the part of

our resistance surveillance that looks

at um healthy pigs and poultry and it's

also structured in such a way that it's

that the results are reflective of the

um of the full UK uh population. So we

can we can apply these um the the

results from this as as applicable to

the to the UK.

So we have various outcome indicators

and this is our primary outcome

indicator for the indicator bacteria

E.coli. Um and this combines the pig

results and the poultry results um in a

clever way so that we have a continuous

because they they alternate to have pig

years alternated with poultry years but

this combines all of them so that we

have an indicator that represents all of

the data for across the two um two two

sampling years. So our primary outcome

indicator is um full susceptibility. So

in other words, um any of the any of the

panel of antibiotics um would treat the

um the E.coli that's that's taken from

these isolates.

Over the years, we've seen an increase

and that's what we want to see with um

full susceptibility. Um but in the last

year, we've seen um a a drop in um the

level of full susceptibility. um even

though we do have decreasing antibiotic

use um in the poultry sector. Um

and perhaps to give you a little bit of

additional granularity on the um uh on

the data behind this from the poultry

year which we've been reporting against

in the VA report. Um so the poultry is

made up of broilers and turkeys here and

you can see that um on the full

susceptibility the primary indicator

that was um shown in the previous slide

we have this drop here um in full

susceptibility in broilers we don't see

that in Turkey so it's the it's the

broiler data that's um essentially um

contributing to that um to that drop in

um in full susceptibility in the primary

indicator um and I'll look a little bit

um further into what's what what what's

underlying that in the next slide. But

before I move on, I think the other

thing to note is of course that um there

we're also seeing a an upward trend by

the looks of it in multi-drug

resistance. So this is one of the

secondary um indicators multi-drug

resistance. So, we want this to be going

down um which it it is by and large in

the in the um in the data that we have

and it is when we combine the um when we

combine the pig and poultry data. Um but

and there's only a tiny increase here on

on on the turkey um on the turkey trend,

but but it's there's still a bit of an

upward trend. So, it's something

something that that we'll keep an eye on

in future years. So then I promised a

closer look at the broiler data um the

boiler susceptibility data um and what

you can see here is that there are a

couple of areas where we're seeing um

increasing um uh resistance trends but

we're seeing them in what we've got here

we've got ampellin um and sulfoxol so

we're seeing them in firstline

antibiotics so this isn't something that

we are getting alarmed about at this

stage because um this is definitely

reflect ive of the kind of antibiotics

that that we would um be seeing as I say

in firstline um treatments. This isn't

any change in in the critically

important antibiotics or or anything

like that. Um so this is the explanation

that that we have at present. As I said,

it's also not driven by the usage data

that we're seeing um in the um in the

usage part of the report. So um I think

that's probably as much as we can say on

it at the moment. We we we need to keep

an eye on it. It's it's one year's

result. It's not a trend. Um let's see

what comes up in um in in in further in

further years. And you can see here that

this is the um HPCIA graph on the right

hand side. And you can see that we're

not you know things things are overall

in terms of trends um still looking encouraging.

So if we have a look at the secondary

outcome indicators um I mentioned uh the

secondary outcome indicators um a couple

of slides ago. So um multi-drug

resistance so we're seeing that

decreasing multi-drug resistant trend um

despite that reduction in in full

susceptibility the trends for multi-drug

resistance are are are still on track

and we're still seeing low levels so

these here resistance cyprfluxin um and

the esbl um ampsy producing ecoli we're

seeing that these are still remaining

low so again all of these again are

reasons for us not being too alarmed by

that change in the um in the primary indicator

indicator

um and and certainly helps to to to be

reassuring on that.

So then if we move um away from those um

indicators um and have a look at

something a little different. Now we um

we've looked at resistance um cyprfluxin

resistance to camplabata juni from from

broilers in the um uh and and turkeys

and um and we are concerned about

cyprloxxicin as it is a highest priority

critically important antibiotic and it's

also one which is used um for um the

treatment of campobacttor um infections

um when they arise in people um

sometimes um and so that's why we um we

have a look at this one but this is

we're bringing this up not it's not

reflective of of use in um in in poultry

because we know that there's been

minimal to certainly in broilers where

we're really looking at boilers because

we're not seeing a a clear trend in

turkeys but we are still seeing an

upward trend in cyprloxin resistance in

campellactine in um broilers we know

this isn't consistent this isn't due to

use um in in broilers because there's

been minimal to to no use um of cyprin

in broilers over that time and this is

really um as that cautionary tale that

we know that sometimes when resistance

arises it doesn't go away again after we

reduce the um the use of an antibiotic.

So this is one of the reasons this is a

message to every sector every every

every prescription of any antibiotic

that um that it's so important to only

use it when absolutely necessary because

just occasionally a resistance arises

that hangs around whatever you do after

that point.

Um right. So um now this slide um uh is

to tell you about um a a new well it's

not that new we've been we've been

looking at it for the last um two to

three years um entricous um species. So

what we're looking at here is an

indicator um gram positive um bacterial

species. So Ecoli tells us it's good

indicator for um resistance in gram

negatives. um entrica species um tell us

what's going on um in terms of

grandpositive organization uh organisms um

um uh and so of course we we're a bit

early for trend data. We haven't got

trend data to look at. We've just got

some um some initial findings where we

have found some resistance um some

vankcomy resistant entrockey in in

broilers and turkeys um which again is

is can't be directly attributed to um

can't attribute that to the use of

vankcomy in in boilers and turkeys

because it's not used in those species.

Um and instead it's it's a it's a good

um example of where when we find things

it helps us to look for where the

resistance has originated um and um and

whether and if so what um can be done to

um to uh uh look into um mitigation

measures. So um this is sort of for

information at the moment. We look

forward to having trends and we're also

doing some more investigations to see if

we can identify where these have um we

these have originated from.

Um including that that one health

message that you know if if if we're

seeing things that are arising in um in

animals um from non-animal sources. So

for example, is it coming via wildlife

or via water courses? Um then it's

important. It reinforces that one health

message um of needing to understand

transmission pathways and and stop

things getting into um uh getting into

farm animals that don't originate there.

And then the last um surveillance update

is on the clinical surveillance. So the

clinical surveillance is the um the part

of um the scanning surveillance. So

samples coming in um submitted by vets

to government labs.

Um and um one thing that we've done this

year for the first time is is pulled out

trend data. So the scanning surveillance

isn't representative of the UK. Um so we

can't say that you know this is this is

the UK picture in the same way as we can

for the harmonized monitoring. However,

we can can look at the the trend data

which we've got here and you can see

here um for ecoli for various different

species here um that we are overall

seeing a reduction in resistance. What

you're looking at here is what we call

um uh isolates of E.coli with limited

treatment options. Um that's a little

bit like multi-drug resistance, but it's

it's different because we use different

break points. looking at um uh a break

point that's more consistent with um how

this could this be clinically treated or

or not could it not be clinically

treated. I I won't go into detail

because I'm I'm I'm sure I'm already

running over with my time. Um do look in

the VA report for um for for further

definitions if you're interested. Um but

you can see here that the the overall

reductions in um in resistance are

they're kind of mirroring the picture

that we're seeing in the harmonized

monitoring. Um and this is particularly

um uh valuable to us because of course

the harmonized monitoring only covers

pigs and poultry whereas here we have um

we have other species too noticeably

cattle and sheep. Um

and then if we take a um a slightly more

detailed look at um at some of this. So

if we if we look at um the ecoli isol

isolated from pigs over time

um you can also um it lets you detect

areas where trends are sometimes going

in the other direction from that that

high level. So here for example um you

can see it's a it's a it's a a shallow

slope but you can see a trend for um

increasing neomy resistance in pigs and

that does correlate with am increasing

amoglycide use in that species over the

last 10 years but you see reductions

nice reductions in trends in um uh in

most of the other ones that we're seeing

here. So really we're seeing that 10

years um of data is is really helping us

to um having having those trends is is

really helpful for being able to take

that long-term view um and and not try

and make sort of knee-jerk um uh draw

knee-jerk conclusions from um from data

coming in over one or two years.

Um, and I guess that the the last point

to make on this slide and and and the

others before is that of course these

reductions in resistance by and large

are mirroring the reductions in AMU that

we saw in the first part of the um presentation.

presentation.

And then um finally Salmonella finally

for the um for the purely resistance um

slides salmonella. So these come from

the um national control program. we have

therefore lots of isolates. Um

essentially um the main message here is

the full susceptibility which is what

we're looking at here. So the ability to

treat um these bugs um from the these

isolates with um any of the antibiotics

in the panels tested is going up overall

in most of um these um uh these

groupings um except for feed. Um but

again that that also correlates with the

overall picture. So reducing amu um

increasing susceptibility reducing

resistance um as a as an overall picture

and then that um is nicely captured with

this coming back to the indicators. We

have our antimicrobial sales data from

the first data slide I showed you in the

blue line and then the multi-drug

resistance indicator coming down here

with these bars. And that really nicely

shows how the um how those those trends

are um are showing the same direction of travel.

travel.

So to summarize um

we're showing good reductions in

antibiotic use um uh in as reflected by

the sales um across the UK and that's

backed up by a by a slightly more mixed

picture in usage across the different

sectors. But we know that that reflects

the different challenges that each

sector is um is encountering as well as

um the the the the great work and the

and the huge energy that people are

putting into making those changes. Um

and as I've outlined, the overall

picture on resistance resistance is is

is always complicated, but the overall

picture, as I hope I've been able to

show you, is encouraging. Um but and I

know I said this last year, this is

still true. If upticks in usage um

become trends, then we must expect to

see this reflected in the AMR levels

just as we're seeing on the mo for the

most part back to June accepted um as

we're seeing um resistance um trends go

down with um trends for for usage um

going down. And this is important

because um resistance ultimately is what

we're trying to mitigate. We're trying

to um we're trying to um

reduce as far as possible the levels of

resistance and and and ultimately

resistance is the is the um factor that

we look at when we see whether or not

how well we're uh when we're when we're

evaluating how well we're doing in our

in our initiatives. And then finally,

some some resistance can't um be very

easily explained by our usage data. And

so we are continuing to um uh improve

where we can the surveillance um that

we're doing introducing new um

indicators. Um but also um uh it's

important that that this trend of

continuous improvement in surveillance

is not just happening in in the

surveillance that we're responsible for

but also in in the other sectors. So

coming back to that one health approach

um I'll leave you on the note that um

one of the other things that we've um

been doing as part of our continuous

improvement is um we've launched a new

interactive data dashboard.

So um you can see there's a QR code here

on the top right. Please do um feel free

to um go and have a play. It allows

users to interrogate the sales and

resistance data um going back to um 2014

um and play with some of the things like

quantities of antibiotics, roots of

administration um and um AMR outcome

indicators. And there is another um QR

code there to please do give us feedback

on the VAR report. Um we are always

looking for um ways to improve um in all

sorts of ways. And that is the end of my

slide. Thank you very much.

That's brilliant. Thank you so much,

Kitty, for that. Um, and yeah, really

exciting for metric geeks like me to see

the new metric coming in for reporting.

Um, but yeah, a really important point

to focus on the trends rather than the

numbers as we transition between them.

I'm also really excited by the new

dashboard. I'm really looking forward to

having a play around with that actually.

Um, which says a lot about me, I think.

Right. Thank you very much. I would like

to now hand the floor over to Cat

Mclofflin from Rumor Agri who is going

to share details of the latest targets

task force report. So over to you Cap.

Thank you Gwen. Um right just let me get

my screen up. Um

it's loading. It's getting there.

>> You'll do better than me, Cat. You can't

Don't know. It says it's still working

on it. So fingers crossed.

I'll let you know once I can see it on

It's saying that there's a problem. So

again, much like much like Kitty, it

Yeah, I'm not sure what's going on with

Teams this morning, but it's it's not

liking sharing slides, is it? Hang on,

something's happening. Aha, we have slides.

slides.

>> Yay. Good. I'll hand over to you then.

Thanks. Thank you. Right. So, thank you

everyone. Um I'm here as as rumor chair,

rumor agriculture chair. And I'm going

to um just give you a run through the

latest rumor target task force 2 report,

the TTF2, which um was released today, I

think it was, and summarizes the fifth

year of progress against the current

cycle of targets across all UK livestock

sectors for data collection, use of

antibiotics, uptake of preventative

measures such as vaccines and training,

as well as the development of industry initiatives.

initiatives.

So this report is the last of the TTF2

cycle and marks another important and

valuable phase in the livestock

industry's antibiotic stewardship

journey and we'll be releasing the third

cycle of targets TTF3 next week.

We're now at the end of this current

cycle of targets and they have continued

to build on the successful

implementation of the first set of

targets released back in 2017.

And as we are seeing from the latest

bars report, overall sales have reduced

now by nearly 60% since 2014.

Rumor is also pleased to see that data

published earlier this year by the

animal plant and health agency APA and

the BMD reveals a strong link between

reduced antibiotic use and reduced

antimicrobial resistance in UK animals

which is testament to the ongoing work

and commitment of UK livestock sectors

who have achieved these results through

continued voluntary efforts and collaboration.

collaboration.

As we've heard from Kitty, national

usage figures remain low and largely

unchanged from last year. And the

long-term AMR surveillance work carried

out by the BMD shows multi multi-drug

resistance in animals is at its lowest

level in a decade. This is something

that UK agriculture should be very proud

of. I'm certainly very proud of the

sectors and efforts that I've seen.

What we know from both the TTF and VAR

reports is that the 2024 was yet another

year of great effort and commitment from

across UK livestock sectors in the

responsible use of antibiotics. The

total quantity of antibiotics sold for

livestock remains at the lowest level to date.

date.

Whilst there is broadly a positive story

to report back on, as we have heard,

there are some increases in usage in

some sectors which have been the result

of disease outbreaks such as aven

influenza and blue tongue, vaccine

shortages, ongoing impacts from Brexit,

as well as environmental influences. All

of which can adversely impact medicine

use in many sectors.

While reductions in use have been

significant over the past decade, as

expected, we are starting to see

reduction levels stabilizing for many

sectors as practices encouraging good

stewardship become ever more mainstream.

I make no apology for stating once again

that antibiotics remain a critical tool

in a vet's medicine cabinet and even

with the best husbandry standards,

animals can fall ill due to disease

outbreaks or as a or as a result of

environmental impacts which can mean

antibiotics are necessary at times to

treat animals and prevent unnecessary suffering.

suffering.

There will always be challenges, but

this has not deterred commitment to the

TTF targets. And the sectors we

represent at Rumor Agriculture have a

strength, determination, and resilience

that we should all be incredibly proud

of. A resilience that is reflected in

the continued efforts and achievements

which are summarized in our latest TTF report.

Some sectors have recorded their lowest

use to date, while others have recorded

increases in use in response to disease

outbreaks, demonstrating the importance

of maintaining access to antibiotics

when it is appropriate to do so.

All sectors continue to strive to keep

antibiotics effective and fit for

purpose and only used when necessary. Of

particular note again in this year's

report is the inclusion of further

medicinehub data which give an

indication of antibiotic use in

ruminants. This is the third collected

data set of antibiotic data from medicinehub.

medicinehub.

It's important to note that the

ruminance sector is incredibly complex

compared to other sectors and designing

a centralized hub to collect data is no

small undertaking. These are still early

data but give an indication of

We've seen a lot of collaboration

promoting responsible antibiotic

stewardship in the sheep, beef, dairy

and calf sectors. This year the report

highlights some of the initiatives and

activities and I really hope that you do

go and read up on them. They've launched

an antibiotic stewardship roadmap to

identify how to further promote and

demonstrate responsible antibiotic

stewardship at UK ruminant farm level to

drive progress and enhance animal health

and welfare. This will also help the

sector to work in partnership with other

ongoing initiatives to strengthen

existing activity to co-design a unified

framework for the collection and

reporting of sufficient evidence of

antibiotic usage at UK national level to

satisfy both customers and authorities.

The vets servicing the sectors are

continuing with their upskilling agenda

driven through the farm vet champions

network and best practice in veterary

medicine's prescribing courses rolled

out in vet school so that the next

generation of farm animal vets can come

into the workforce informed and on

point. We've got various initiatives

ongoing which support health planning

and surveillance, pharma training and

earned recognition. All of these helped

cushion the animals under our care from

challenges such as disease incursions

while protecting our trading reputation.

The third correlated data set of

antibiotic use in the UK cattle and

sheep sectors totals 8,878

enterprises across dairy, beef and

sheep. These are still early data but

they do give an indication of antibiotic

use in ruminance.

At the time of the rumor TTF report

going to print, Medicine Hub drew on

data from 3,25

dairy enterprises to calculate a mean

usage of 13.94 MIGs per per pcu, not a

full year of data. This is comparable to

the MIGs per PCU figure contained in the

UK VAR report as the denominator that's

the number of adult dairy cows and

adjusted live weights used in

MedicineHub are identical.

In population terms, this represents 43%

of adult dairy cows in the UK.

The Medicine Hub figure for HPCIA use in

dairy was low at 0.01 mg per pcu.

We had 3,367

beef enterprises including rearing

calves to calculate a mean antibiotic

usage of 1.7 mg per kilogram. Mean HPCIA

use was 0.002

mg per kilogram

and a total of 2,36

sheep enterprises were submitted at the

time of the rumor TTF report going to

print. Again, not a full year of data

with coverage equivalent to 10% of the

UK sheep population.

Mean antibiotic usage was calculated to

be 6.5 mix per cake and this differs

slightly from the figures contained in

the UK vase report.

There has been ongoing and considerable

pro progress in the sheep industry

efforts towards responsible antibiotic

stewardship despite a challenging

environment in 20 uh 2024.

The sheep antibiotic guardian group

together with the sheep veterary society

have issued clear guidance to vets to

ensure appropriate prescribing takes

place particularly in the face of

challenging vaccine supply and to help

in the practical outworkings of the new

veterary medicine's regulations.

Data to date supports that the sheep

industry are a low user of antibiotics

with very low HPCIA use. The key

challenges of note include significant

vaccine supply disruption which

continued to affect the industry during 2024.

2024.

Most particularly the supply of both

enzotic abortion and clustial vaccines.

We had a second lamming season with

Malenberg virus and blue tongue and

ongoing complexities with data collection.

The TTF report provides lots of updates

from the dairy, beef, and sheep sectors,

and I hope you do read through it all.

The bullet points on the slide

illustrate just some of the headlines

achieved across these reminant sectors.

Sales of injectable, highest priority,

critically important antibiotics in

cattle, has decreased substantially,

down 83% since 2014.

Health and welfare metrics indicate a

reduction in clinical mystitis alongside

a 98% reduction in the sales of

intramory HPCIA products since 2014.

HPCIA use in sheep remains very low

below 0.05% of total use. We continue

though to see challenges in some vaccine

supp vaccine supplies however and this

is a concerning issue which was

discussed in depth in last week's webinar.

The pig sector has continued its

emphasis on responsible use rather than

zero use and animal health and welfare

remain key priorities.

The 2023 and 2024 antibiotic usage

figures are very similar. 2024 is 1.6%

higher than 2023, potentially indicating

a stabilization in usage after the rise

seen between 2022 and 2023.

HPCIA particularly the AEG category B

use remains very low with no Kiston

usage in 2024

and this shows continued commitment by

the pig sector to use antibiotics

responsibly even in the face of

The health challenges that were

referenced in the 2023 rumor TTF report

remain pertinent during 2024.

Cases of swine dentry diagnosed in 2024

rose again on a number of diagnosis.

The pig sector is aware of the impact of

increasing swine swine disintry on

antibiotic usage and has formed an

industry working group to address this.

The problem will require a cross- sector

solution and the sector has been

fortunate in working with the AMAST

that's AMR in agri food systems

transdisciplinary network to help

achieve this.

General interenteric health has been

less stable. The number of diagnosis of

diarrhea or gastroint I can't say this

gastrointestinal issues as the main

presenting sign was 522

in 2024

versus 399 in 2023

and that's data from the GP pig disease

surveillance dashboard.

Vaccine availability issues have also

continued throughout 2024 impacting

health management and disease prevention strategies.

In 2024, the Scottish salmon farming

sector continued to focus on the

responsible use of antibiotics,

balancing the need to protect fish

health and welfare with a global aim to

reduce use.

Salmon farmers recorded a decrease in

the volume of antibiotic used with use.

The lowest insect figures were first

collected and published in 2017,

4.9 mg per kilogram versus a target of 5

mg per kilogram,

which means that the sector has achieved

its TTF2 target.

Decreases were observed across both the

freshwater and marine phases of

production. Treatments are still limited

to a relatively small number of farms

each year with 10.6% of freshwater farms

and 7.1% marine farms undertaking an

antibiotic treatment in 2024.

Use of both oxyetracyc and flororophenol

decreased in 2024. Similar to previous

years, there was no use of oxalinic acid

which is defined as a higher priority antibiotic.

antibiotic.

Salmon are farmed in the wild wild locks

around Scotland's coastline. They're

sensitive to environmental changes which

can have direct impacts on the fish, but

which more often impact the development

and proliferation of some of the harmful

organisms that can impact fish health

and welfare.

Since 2022, the sector has experienced

challenging conditions in the marine

environment where salmon are farmed with

increased water temperatures and oceanic

changes further a field. Changes in the

marine environment can impact fish

health which in turn may in some

circumstances lead to a requirement for

treatment intervention.

The salmon farming sector has made

significant investment in new

technological developments and

innovation to support fish health

management eg increased environmental

monitoring and new health interventions.

For example, a recent report

demonstrates nearly a billion pound

investment in fish health and welfare

since 2018.

This has led to significant improvements

in fish health and survival in 2024,

which is reflected in antibiotic use.

Scottish salmon farmers are proud of the

progress made in 2024 and will remain

vigilant by continuing to monitor their

fish and the farming environment on a

daily basis, promptly reacting wherever

The trout sector has seen antibiotic use

decrease by 26%.

Um, between 2023 and 2024

from 6.9 mg per kilogram to 5.1 mg per

kilogram. This is the lowest figure seen

since data was first published in 2017.

The only HPCIA used in trout is a

quinolone oxylinic acid and its use

decreased by 26%.

From 1.8 8 migs per cake in 2023 to 1.5

migs per cake in 2024.

This is also the lowest figure recorded

and represents a reduction of 78% since 2017.

2017.

The industry remains committed to to

decreasing usage and there is no

prophylactic usage of antibacterials in

the sector.

The track sector is still undergoing

changes with a move towards larger fish

production through the production cycle.

This means that farms buy fewer fry to

grow on. Stocking densities are then

lower and fewer problems are seen. The

extreme weather conditions remain a

concern and can cause higher water

temperatures which at times can prove

challenging for some farms. The sector

though is always looking at ways of

mitigating issues caused by extreme weather.

weather.

Availability of vaccines in 2024 was a

challenge and this puts stock at a

higher risk of disease challenges and in

circum and in some circumstances an

game birds um game birds feed compounded

with antibiotics fell approximately 25%

in 2024 although this was offset by an

increase in soluble use and the small

increase in overall use of 5%. However, there has been a sustained

However, there has been a sustained shift across the sector towards more use

shift across the sector towards more use of penicellin in the last 8 years, up by

of penicellin in the last 8 years, up by 33% in real terms, while overall

33% in real terms, while overall antibiotic use has fallen by 48% in the

antibiotic use has fallen by 48% in the same period, indicating a significant

same period, indicating a significant shift away from the more important

shift away from the more important antibiotic groups.

antibiotic groups. Treatment with penicellin does require a

Treatment with penicellin does require a much greater amount of active ingredient

much greater amount of active ingredient than some other antibiotic groups. So

than some other antibiotic groups. So achieving this against the backdrop of a

achieving this against the backdrop of a 40 of a 48% overall reduction represents

40 of a 48% overall reduction represents sustained progress and remember

sustained progress and remember penicellin fall into the lowest priority

penicellin fall into the lowest priority group of antibiotics

throughout the TTF2 cycle. The sector has seen volatility in antibiotic use.

has seen volatility in antibiotic use. However, this has been mirrored to a

However, this has been mirrored to a certain extent by volatility in

certain extent by volatility in production levels mainly due to CO 19

production levels mainly due to CO 19 and aven influenza.

and aven influenza. Consequently, the sector has not met the

Consequently, the sector has not met the targets set for the TTF2 period on

targets set for the TTF2 period on overall antibiotic use. There has been a

overall antibiotic use. There has been a meaning a meaningful reduction in the

meaning a meaningful reduction in the use of compounded infeed antibiotics

use of compounded infeed antibiotics encouraged by a growing focus on

encouraged by a growing focus on responsible prescribing practices by

responsible prescribing practices by specialist game bird vets and bird

specialist game bird vets and bird management. such as a health risk

management. such as a health risk assessment matrix for release pens. The

assessment matrix for release pens. The sector remains committed to ensuring

sector remains committed to ensuring this approach to responsible prescribing

this approach to responsible prescribing is adopted across the sector.

is adopted across the sector. The game sector has exceeded its target

The game sector has exceeded its target for both for total HPCIA use by

for both for total HPCIA use by achieving a 19% reduction during the

achieving a 19% reduction during the TTF2 period and as a percentage of total

TTF2 period and as a percentage of total use has kept below 0.5% throughout the

use has kept below 0.5% throughout the TTF2 cycle. The sector need needs more

TTF2 cycle. The sector need needs more support by way of scientific research

support by way of scientific research and enforcement to meet the ambitious

and enforcement to meet the ambitious targets set for TTF2. In the short term,

targets set for TTF2. In the short term, progress resulting from improved

progress resulting from improved infrastructure and production release

infrastructure and production release systems will be much longer work will be

systems will be much longer work will be a much longer work stream.

In 2024, data collected by the British Egg Industry Council, the BEIC,

Egg Industry Council, the BEIC, represented around 90% of the laying hen

represented around 90% of the laying hen industry. The antibiotic use of the

industry. The antibiotic use of the sector in 2024 was 0.28%

sector in 2024 was 0.28% birthdays treated in 2024, which

birthdays treated in 2024, which continues to be below the target of 1%

continues to be below the target of 1% bird days treated.

bird days treated. During 2024, the national flock expanded

During 2024, the national flock expanded by over 2 million birds once again. So

by over 2 million birds once again. So this results represents a significant

this results represents a significant achievement.

achievement. Since 2016, the sector has reduced its

Since 2016, the sector has reduced its antibiotic usage in bird days treated by

antibiotic usage in bird days treated by 58%.

58%. The industry also remains below its

The industry also remains below its HPCIA usage target of 0.05%

HPCIA usage target of 0.05% bird days.

bird days. During 2024, an HPCIA was used for the

During 2024, an HPCIA was used for the first time since 2016 in a breeder

first time since 2016 in a breeder laying flock and not for birds producing

laying flock and not for birds producing eggs for the food chain. This related to

eggs for the food chain. This related to a single course of treatment.

a single course of treatment. BEIC only permits the use of

BEIC only permits the use of fluoricquinolone in the treatment of

fluoricquinolone in the treatment of significant cases of disease where other

significant cases of disease where other treatments have failed to achieve the

treatments have failed to achieve the required outcome and where the case has

required outcome and where the case has been reviewed and a deriggation for

been reviewed and a deriggation for treatment issued.

The poultry meat sector has achieved remarkable reductions in antibiotic use,

remarkable reductions in antibiotic use, emphasizing responsible stewardship and

emphasizing responsible stewardship and transparency.

transparency. Total antibiotic use has decreased by

Total antibiotic use has decreased by 83.22%

83.22% since 2012 with broiler chickens at

since 2012 with broiler chickens at 11.33 mg per pcu and turkeys at 40 mg

11.33 mg per pcu and turkeys at 40 mg per pcu. In 2024,

per pcu. In 2024, use of HPCIA has decreased by 99.34%

use of HPCIA has decreased by 99.34% since 2012, prescribed only as a last

since 2012, prescribed only as a last resort. The sector's commitment to

resort. The sector's commitment to responsible use is reflected in ongoing

responsible use is reflected in ongoing monitoring and collaboration.

There have been many industry initiatives that have been developed in

initiatives that have been developed in recent years which further demonstrate

recent years which further demonstrate the industry's commitment to tackling

the industry's commitment to tackling AMR. All of these initiatives that you

AMR. All of these initiatives that you see on the screen have been generated in

see on the screen have been generated in the last 10 years highlighting the unity

the last 10 years highlighting the unity and collaboration that is embedded into

and collaboration that is embedded into the industry. In particular, a

the industry. In particular, a commitment to data collection, training

commitment to data collection, training and best practice.

I want to acknowledge the huge commitment that the livestock sectors

commitment that the livestock sectors have made over recent years and that

have made over recent years and that continued commitment. There is still

continued commitment. There is still ongoing commitment and the industry

ongoing commitment and the industry continues to challenge itself and ask

continues to challenge itself and ask questions which continues to drive

questions which continues to drive responsible use of medicines where

responsible use of medicines where needed as little as possible and as much

needed as little as possible and as much as necessary.

as necessary. I really hope as we finish this round of

I really hope as we finish this round of TTF2 that everyone that's on here today

TTF2 that everyone that's on here today does actually come and join us again

does actually come and join us again next week for the the launch of the TTF3

next week for the the launch of the TTF3 um next weddednesday. I think it will be

um next weddednesday. I think it will be a really good session and will will help

a really good session and will will help to emphasize the continued commitment

to emphasize the continued commitment that the sector is showing

that the sector is showing and that's me. Thank you. I will now

and that's me. Thank you. I will now stop sharing. Gwen,

>> thank you so much Cat. That was um yeah it's really great to see all the work

it's really great to see all the work that's being done and yeah I think it's

that's being done and yeah I think it's really important you know that you've

really important you know that you've noted the impact that the current

noted the impact that the current disease challenges that the different

disease challenges that the different sectors have been facing and also some

sectors have been facing and also some of the issues we face with vaccine

of the issues we face with vaccine availability um and that everyone has

availability um and that everyone has that in mind as well and it just goes to

that in mind as well and it just goes to show that despite these challenges we're

show that despite these challenges we're still you know seeing a really positive

still you know seeing a really positive um positive

um positive bit of progress. Um, so

bit of progress. Um, so what we will do now is move on to some

what we will do now is move on to some questions for you both. I believe that

questions for you both. I believe that most of the questions that have come up

most of the questions that have come up in the Q&A have been answered um by the

in the Q&A have been answered um by the team. So, thank you very much to the

team. So, thank you very much to the team for getting through some of those.

team for getting through some of those. I'll come back to some in the end if we

I'll come back to some in the end if we have time that have been unanswered. But

have time that have been unanswered. But I do have some questions for you both as

I do have some questions for you both as well. Um, so I'll start off. The details

well. Um, so I'll start off. The details that we've heard today are largely

that we've heard today are largely positive and the sales of antibiotics

positive and the sales of antibiotics for use in food producing animals

for use in food producing animals remains stable, which is great. Um, but

remains stable, which is great. Um, but we are also seeing a bit of a mixed

we are also seeing a bit of a mixed picture in usage trends when we look

picture in usage trends when we look across the different sectors and some

across the different sectors and some have recorded upticks in use as you've

have recorded upticks in use as you've both kind of recognized um, in your

both kind of recognized um, in your presentations with others recording

presentations with others recording their lowest use to date.

their lowest use to date. Do we feel perhaps that we're now at a

Do we feel perhaps that we're now at a bit of a natural point in this process

bit of a natural point in this process where we expect to be seeing a bit of a

where we expect to be seeing a bit of a leveling off or a plateau in the

leveling off or a plateau in the reductions in use? Um because we've seen

reductions in use? Um because we've seen such significant reductions over the 5

such significant reductions over the 5 to 10 years. Um and that's I guess to

to 10 years. Um and that's I guess to Kitty first and then to Cat if that's

Kitty first and then to Cat if that's all right.

all right. >> Thanks Gwen. I mean yeah it's a really

>> Thanks Gwen. I mean yeah it's a really good question isn't it? and um and it

good question isn't it? and um and it really gets to the heart of sort of the

really gets to the heart of sort of the the interplay between between

the interplay between between surveillance and setting targets and and

surveillance and setting targets and and doing doing doing the work. Um,

doing doing doing the work. Um, so I think there's I think that we're it

so I think there's I think that we're it it is natural that we're seeing a

it is natural that we're seeing a leveling off um in one sense in that um

leveling off um in one sense in that um I think that the things that were more

I think that the things that were more straightforward to do are the things

straightforward to do are the things that get done first and that's

that get done first and that's absolutely natural and and a normal part

absolutely natural and and a normal part of the process and then the things that

of the process and then the things that are more challenging to do or or you

are more challenging to do or or you know when when things um I mean cat

know when when things um I mean cat really nicely outlined a lot of the

really nicely outlined a lot of the challenges that some of the sectors are

challenges that some of the sectors are facing when you get into that then then

facing when you get into that then then I think that is is one reason for for

I think that is is one reason for for seeing a leveling off but there's

seeing a leveling off but there's another question here which is um is the

another question here which is um is the leveling off and I think you you you put

leveling off and I think you you you put this as part of your question is the

this as part of your question is the leveling off um indicative of the well

leveling off um indicative of the well that's that's the level that we've

that's that's the level that we've reached now and and and that's the level

reached now and and and that's the level that since we've leveled off we should

that since we've leveled off we should that that's that's it that's where we we

that that's that's it that's where we we meant to land and I think that for that

meant to land and I think that for that I would say again I'd bring it back to

I would say again I'd bring it back to the measurement and the AMR what we need

the measurement and the AMR what we need to do is

to do is the what we the the sales data and the

the what we the the sales data and the usage data measures people's behavior in

usage data measures people's behavior in in what's being done on the ground and

in what's being done on the ground and and and prescribing behavior and usage

and and prescribing behavior and usage behavior, but the AMR data tells us what

behavior, but the AMR data tells us what the bacteria's response to this behavior

the bacteria's response to this behavior is. And so we have to look our data to

is. And so we have to look our data to see if this is if this is efficient, if

see if this is if this is efficient, if we're getting the um the resistance low

we're getting the um the resistance low enough um to keep antibiotics working in

enough um to keep antibiotics working in animals and also to make sure that um

animals and also to make sure that um our public health colleagues are not

our public health colleagues are not concerned about um about the levels of

concerned about um about the levels of of AMR that we're seeing and the kinds

of AMR that we're seeing and the kinds of AMR that we're seeing in animals from

of AMR that we're seeing in animals from a human health perspective. Um, so I

a human health perspective. Um, so I think that bringing that back round to

think that bringing that back round to the to the targets angle, you have to

the to the targets angle, you have to we all have to, so we in government and

we all have to, so we in government and and and as all all the great work that

and and as all all the great work that Cat's been telling us about with the

Cat's been telling us about with the targets task force, everything that

targets task force, everything that we're doing, we have to keep on looking

we're doing, we have to keep on looking at all of these different threads and

at all of these different threads and matching them up and making sure that um

matching them up and making sure that um that that we're doing the right thing

that that we're doing the right thing and the things that we're doing having

and the things that we're doing having are having the effect that we that we

are having the effect that we that we want them to have. So basically yes it's

want them to have. So basically yes it's it we've seen some really great progress

it we've seen some really great progress um but we we should never stop um

um but we we should never stop um looking and challenging ourselves and

looking and challenging ourselves and making sure that even when usage is low

making sure that even when usage is low that the usage is necessary because even

that the usage is necessary because even in some sectors where usage is low that

in some sectors where usage is low that there's still room for improvement in

there's still room for improvement in actual stewardship. Um but that I really

actual stewardship. Um but that I really don't want that to take to to take away

don't want that to take to to take away from the um the recognition of how

from the um the recognition of how incredibly well um all the sectors have

incredibly well um all the sectors have done in in achieving the reductions that

done in in achieving the reductions that we've we've seen in the trends that that

we've we've seen in the trends that that we've all been talking about. Thanks.

we've all been talking about. Thanks. >> Thanks Kitty. And yeah, it's kind of

>> Thanks Kitty. And yeah, it's kind of that continuous improvement model, isn't

that continuous improvement model, isn't it, of perhaps some of the lowhanging

it, of perhaps some of the lowhanging fruit have been picked now, but there is

fruit have been picked now, but there is still nuance and nitty-gritty that we

still nuance and nitty-gritty that we can get into um with that cat. Did you

can get into um with that cat. Did you have anything to add on that?

have anything to add on that? >> Yeah, I mean certainly, you know, I've

>> Yeah, I mean certainly, you know, I've been involved with with the TTF since it

been involved with with the TTF since it since it first started and I think

since it first started and I think you're right. there has been an element

you're right. there has been an element of you know lowhanging fruit was was

of you know lowhanging fruit was was picked off first and we always

picked off first and we always anticipated that at some point we would

anticipated that at some point we would start to see sectors starting to level

start to see sectors starting to level off um their use of antibiotics as they

off um their use of antibiotics as they start to reach that kind of sweet spot

start to reach that kind of sweet spot of responsible use in response to

of responsible use in response to protecting animal health and welfare.

protecting animal health and welfare. I think though it's it's important to

I think though it's it's important to remember probably two things.

remember probably two things. industry's efforts have never been about

industry's efforts have never been about a race to the bottom. We've never been

a race to the bottom. We've never been about achieving zero use. So, we need

about achieving zero use. So, we need antibiotics in our um to protect animal

antibiotics in our um to protect animal health and welfare. So,

health and welfare. So, will all um I think to meet that need be

will all um I think to meet that need be an element of having to use antibiotics.

an element of having to use antibiotics. I think as well the other thing that

I think as well the other thing that that's important is that we've never

that's important is that we've never known what that quantitative level um of

known what that quantitative level um of of that kind of stable spot and the

of that kind of stable spot and the sweet spot would be for each sector. So

sweet spot would be for each sector. So I think probably what we'll start to see

I think probably what we'll start to see is is some sectors probably have reached

is is some sectors probably have reached that sweet spot and you know there might

that sweet spot and you know there might be a few fluctuations every now and then

be a few fluctuations every now and then but I think they'll kind of you know

but I think they'll kind of you know generally um as I say be stabilizing

generally um as I say be stabilizing while other sectors have still got a bit

while other sectors have still got a bit of work to do and you know I think

of work to do and you know I think that's just something that that we have

that's just something that that we have to we have to take and view and assess

to we have to take and view and assess you know every year and as ongoing but

you know every year and as ongoing but but I don't I don't think there has been

but I don't I don't think there has been any loss of enthusiasm to keep doing

any loss of enthusiasm to keep doing what we're doing and to keep recognizing

what we're doing and to keep recognizing why we're doing this. Um and I think

why we're doing this. Um and I think that's probably one of the main things

that's probably one of the main things that that I would take from um from the

that that I would take from um from the results that we've seen at the minute.

results that we've seen at the minute. >> Brilliant. Thank you. And it's really

>> Brilliant. Thank you. And it's really motivating to see, isn't it, that that

motivating to see, isn't it, that that enthusiasm is still there as we enter

enthusiasm is still there as we enter this kind of perhaps new phase of

this kind of perhaps new phase of needing to think a little bit more about

needing to think a little bit more about those reductions. We've, as I said, done

those reductions. We've, as I said, done the lowhanging fruit bit to some extent

the lowhanging fruit bit to some extent in some sectors and it's going to be

in some sectors and it's going to be more detailed conversation from from now

more detailed conversation from from now on, but keeping that motivation um that

on, but keeping that motivation um that we are, you know, largely doing a

we are, you know, largely doing a brilliant job is is just so important.

brilliant job is is just so important. Okay, so moving on then to the new

Okay, so moving on then to the new metrics that are coming in that Katy you

metrics that are coming in that Katy you sort of referenced at the very beginning

sort of referenced at the very beginning of your presentation. So these are now

of your presentation. So these are now being used across Europe for calculating

being used across Europe for calculating and commenting on antibiotic use.

and commenting on antibiotic use. Comparisons across countries, you know,

Comparisons across countries, you know, we know that it's fraught with caveats

we know that it's fraught with caveats and there are different structures,

and there are different structures, different markets, but comparisons,

different markets, but comparisons, they're going to be made regardless, I

they're going to be made regardless, I suppose, is the um is the point. So if

suppose, is the um is the point. So if the new out if the outcome of the new

the new out if the outcome of the new metric is that EU countries are going to

metric is that EU countries are going to be courting lower figures from now on,

be courting lower figures from now on, is it important that the UK livestock

is it important that the UK livestock sectors move to these new metrics as

sectors move to these new metrics as well? So any comparisons that are being

well? So any comparisons that are being made are at least being made on similar

made are at least being made on similar data.

data. And yeah, Kitty, I would probably pause

And yeah, Kitty, I would probably pause that to you first again.

that to you first again. >> Thank you. Um, oh gosh. So, I've got so

>> Thank you. Um, oh gosh. So, I've got so many things I want to um weave into my

many things I want to um weave into my um response here. And but actually maybe

um response here. And but actually maybe so, so um if I haven't if I haven't

so, so um if I haven't if I haven't covered everything, Gwen, then do do

covered everything, Gwen, then do do pick me up on something if I forget

pick me up on something if I forget something. Um but um but actually I saw

something. Um but um but actually I saw that there was a question in the chat

that there was a question in the chat that that is something that maybe this

that that is something that maybe this is the right time to to respond to about

is the right time to to respond to about um about how do we compare with with

um about how do we compare with with other European countries. And so

other European countries. And so certainly on the basis of the data that

certainly on the basis of the data that we have at the moment um bearing in mind

we have at the moment um bearing in mind that we haven't yet seen the um this

that we haven't yet seen the um this year's most recent European report

year's most recent European report coming uh come out. I think it's due out

coming uh come out. I think it's due out in the next week or so. Um so we're

in the next week or so. Um so we're comparing with with slightly older data

comparing with with slightly older data but um when we look at that 22 out of

but um when we look at that 22 out of the 29 um uh EU and after countries um

the 29 um uh EU and after countries um reported higher sales um of of veterary

reported higher sales um of of veterary antibiotics for food producing animals

antibiotics for food producing animals than than um than we did and only seven

than than um than we did and only seven therefore sold um less than us um um

therefore sold um less than us um um Slovenia, Latvia, Luxembourg, Finland,

Slovenia, Latvia, Luxembourg, Finland, Sweden, Iceland and Norway. um clearly

Sweden, Iceland and Norway. um clearly reading that not from memory. Um so that

reading that not from memory. Um so that that gives you a

that gives you a that gives you a sort of a picture of

that gives you a sort of a picture of the national sales level. Um I think

the national sales level. Um I think though it's important to remember that

though it's important to remember that on the national sales level, we've

on the national sales level, we've always said it's hard to make direct

always said it's hard to make direct direct comparisons because every country

direct comparisons because every country has a different composition of of of

has a different composition of of of sectors. And so for example, we've got

sectors. And so for example, we've got lots of sheep and other countries have

lots of sheep and other countries have no sheep and other countries have, you

no sheep and other countries have, you know, more pigs than us or or so so you

know, more pigs than us or or so so you you and you've seen the the difference

you and you've seen the the difference in um in how the the metrics are

in um in how the the metrics are calculated at that sector level. And so

calculated at that sector level. And so it gives you a bit of an idea, but it's

it gives you a bit of an idea, but it's it's not a oh yes, we can directly

it's not a oh yes, we can directly compare these two countries. Um

compare these two countries. Um so um with the new metric then so we

so um with the new metric then so we don't yet have the usage data um from

don't yet have the usage data um from the EU because um with the new metric

the EU because um with the new metric because we're looking forward to that

because we're looking forward to that hopefully coming out in the in the new

hopefully coming out in the in the new report and but what that will do um is

report and but what that will do um is um

um it will be applying the same methodology

it will be applying the same methodology at a sector level as we're applying at a

at a sector level as we're applying at a sector level in the VA report and

sector level in the VA report and therefore that will be more um

therefore that will be more um legitimate from a methodology ology

legitimate from a methodology ology perspective to look across and say well

perspective to look across and say well this is the um MIGS per kig usage in

this is the um MIGS per kig usage in this UK sector or what is it in the

this UK sector or what is it in the other UK um sorry other EU countries um

other UK um sorry other EU countries um and therefore there will be a comparison

and therefore there will be a comparison at that level which will be interesting

at that level which will be interesting I think it will be it'll be really

I think it will be it'll be really interesting to see what what what's

interesting to see what what what's going on and where other countries are

going on and where other countries are are finding um they're making that

are finding um they're making that they're I don't know they they're

they're I don't know they they're finding it more straightforward to make

finding it more straightforward to make um uh reductions in use and actually

um uh reductions in use and actually maybe there are going to be some areas

maybe there are going to be some areas where where we've made um uh more

where where we've made um uh more headway than than others and and it's

headway than than others and and it's absolutely an opportunity for learning

absolutely an opportunity for learning and um uh and seeing where we can we can

and um uh and seeing where we can we can learn from others and perhaps others can

learn from others and perhaps others can learn from us. Um but that the part of

learn from us. Um but that the part of your question on should the sectors be

your question on should the sectors be using the new metric in um in the in the

using the new metric in um in the in the targets task force context and and at a

targets task force context and and at a sector level. Well, from our

sector level. Well, from our perspective, um, for the VAS report and

perspective, um, for the VAS report and for national trend data for for sectors

for national trend data for for sectors and for and and for the whole country,

and for and and for the whole country, it makes 100% sense to use something

it makes 100% sense to use something that's that's harmonized with um with

that's that's harmonized with um with other countries in the region. At a

other countries in the region. At a sector level, it is

sector level, it is it is up to the sectors what works best

it is up to the sectors what works best for them because ultimately we'll still

for them because ultimately we'll still have this comparison level in the VA

have this comparison level in the VA report. But um I we absolutely wouldn't

report. But um I we absolutely wouldn't seek to to to dictate to the sectors um

seek to to to dictate to the sectors um what metrics to use. Um and ultimately

what metrics to use. Um and ultimately it's whatever is most useful for for for

it's whatever is most useful for for for each sector and that may be a different

each sector and that may be a different decision for each sector. um in in a

decision for each sector. um in in a tool for being able to reflect having

tool for being able to reflect having that what I was talking about in my

that what I was talking about in my previous answer almost that feedback

previous answer almost that feedback loop. You decide to do something and

loop. You decide to do something and then you measure how well that's going.

then you measure how well that's going. And so whatever chimes best with people

And so whatever chimes best with people who are actually on the ground doing

who are actually on the ground doing that. But I guess that I'm I'm I'm

that. But I guess that I'm I'm I'm veering into cats territory here.

veering into cats territory here. >> I think you've answered it really

>> I think you've answered it really nicely, Kitty. I don't think there's

nicely, Kitty. I don't think there's anything more I can add to that to be

anything more I can add to that to be honest. I think you know the individual

honest. I think you know the individual sectors have they are aware of the the

sectors have they are aware of the the changing metrics that that the virus and

changing metrics that that the virus and things are using. Um they are I think

things are using. Um they are I think most of them have had conversations or

most of them have had conversations or are ongoing with conversations about

are ongoing with conversations about what to do but but ultimately I think

what to do but but ultimately I think you've nicely answered it.

you've nicely answered it. >> Perfect. Thank you both. Um okay so

>> Perfect. Thank you both. Um okay so sticking with data just for a second and

sticking with data just for a second and then I'll ask some questions around the

then I'll ask some questions around the surveillance. Um so cat data you know it

surveillance. Um so cat data you know it remains a priority for all sectors to to

remains a priority for all sectors to to collect this data and some are more

collect this data and some are more advanced in this than others I think

advanced in this than others I think it's fair to say. Um so data collection

it's fair to say. Um so data collection it's been delivered voluntarily to date

it's been delivered voluntarily to date and we know that with the updated um

and we know that with the updated um veterary medicine's regulations there is

veterary medicine's regulations there is now an option to make this data

now an option to make this data collection mandatory in the future. So,

collection mandatory in the future. So, do you feel that the voluntary approach

do you feel that the voluntary approach still has the most merit?

still has the most merit? >> So, Gwen, this is a question that does

>> So, Gwen, this is a question that does come up regularly and rumor has not

come up regularly and rumor has not taken a position on this yet, but what I

taken a position on this yet, but what I will say is the voluntary approach done

will say is the voluntary approach done in the way that we've done it has, I

in the way that we've done it has, I think, galvanized hearts and minds and

think, galvanized hearts and minds and that positivity cannot be overlooked as

that positivity cannot be overlooked as a massive contributing factor to the

a massive contributing factor to the UK's ongoing achievements.

UK's ongoing achievements. Mandating something is not always a

Mandating something is not always a solution to a problem. So if the

solution to a problem. So if the government though through the powers of

government though through the powers of the VMR decide to move in this direction

the VMR decide to move in this direction then we need to determine the what'ss

then we need to determine the what'ss and wise and by that I'm saying what

and wise and by that I'm saying what data is actually needed why is it

data is actually needed why is it required i.e. what question is it

required i.e. what question is it answering? And importantly, we need to

answering? And importantly, we need to understand who would own the data and

understand who would own the data and what can be done with it. The last thing

what can be done with it. The last thing that we, and by we, I'm talking about

that we, and by we, I'm talking about industry, the sectors, government,

industry, the sectors, government, taxpayers. The last thing that we need

taxpayers. The last thing that we need is to create an overly burdensome,

is to create an overly burdensome, expensive reporting and collection

expensive reporting and collection system, which loses that goodwill and

system, which loses that goodwill and just creates duplication of effort and

just creates duplication of effort and concern.

concern. It's also worth reminding the audience

It's also worth reminding the audience today that rumor targets are all and

today that rumor targets are all and have always been about meeting a very

have always been about meeting a very specific need and that's been to reduce,

specific need and that's been to reduce, refine and replace antibiotic use so

refine and replace antibiotic use so that we minimize the risk of resistance

that we minimize the risk of resistance developing in those antibiotics which

developing in those antibiotics which are vital to both animals and humans.

are vital to both animals and humans. So I think as I say it comes back to

So I think as I say it comes back to obviously the industry will do what what

obviously the industry will do what what it's asked to do if if government decide

it's asked to do if if government decide to mandate we will respond to that that

to mandate we will respond to that that um that intention

um that intention but we just need to be very clear what

but we just need to be very clear what we're you say what question is being

we're you say what question is being asked um before we so that we make sure

asked um before we so that we make sure we get the right answer.

we get the right answer. >> Absolutely. And I think, you know, it's

>> Absolutely. And I think, you know, it's human behavior change is one of my areas

human behavior change is one of my areas that I'm really interested in. And the

that I'm really interested in. And the fact that everyone in industry has had

fact that everyone in industry has had agency in this and has been able to take

agency in this and has been able to take ownership of it has been so important to

ownership of it has been so important to and is reflected in what has happened to

and is reflected in what has happened to date, isn't it? But um as you say, we

date, isn't it? But um as you say, we well, we'll see what what happens with

well, we'll see what what happens with this. Kitty, did you have anything that

this. Kitty, did you have anything that you wanted to add to that before we move

you wanted to add to that before we move on to a surveillance question?

on to a surveillance question? >> Thank you. Yeah. Um yeah, just a little

>> Thank you. Yeah. Um yeah, just a little bit. And I'll I'll try not to overlap

bit. And I'll I'll try not to overlap too much with with what Cat said, but I

too much with with what Cat said, but I think it's uh I mean and I agree with I

think it's uh I mean and I agree with I agree with much of what you said, Kat. I

agree with much of what you said, Kat. I mean, I think we bottom line, I think

mean, I think we bottom line, I think hopefully hopefully you've seen from the

hopefully hopefully you've seen from the presentations today how valuable the

presentations today how valuable the data on antibiotic usage is. I mean, it

data on antibiotic usage is. I mean, it tells us it it tells us where we're

tells us it it tells us where we're doing well and where we where we could

doing well and where we where we could improve a bit. It gives us all sorts of

improve a bit. It gives us all sorts of information. Um and hopefully that

information. Um and hopefully that information is also useful. I mean for

information is also useful. I mean for it to work properly that information

it to work properly that information should be useful to the people

should be useful to the people collecting it reporting it for the

collecting it reporting it for the people at the the food processing chain

people at the the food processing chain at the sector level at the national

at the sector level at the national level that's and that's why the um the

level that's and that's why the um the the voluntary um uh way we've done

the voluntary um uh way we've done things so far has um has worked so well

things so far has um has worked so well because as you said you just expressed

because as you said you just expressed it then Gwen saying that everybody's had

it then Gwen saying that everybody's had agency in in developing the system that

agency in in developing the system that actually does work for them and that has

actually does work for them and that has to be that has to be the way um to go

to be that has to be the way um to go for a successful system. Um we don't

for a successful system. Um we don't have any um easy answers. Um I don't

have any um easy answers. Um I don't think there is an easy answer to your

think there is an easy answer to your actual question which one is better or

actual question which one is better or should we be doing one or the other? But

should we be doing one or the other? But actually one of the things we're doing

actually one of the things we're doing at the moment is um is doing a a piece

at the moment is um is doing a a piece of work to um talking to to people in

of work to um talking to to people in the UK but also to um colleagues in

the UK but also to um colleagues in other countries where um different

other countries where um different approaches have been taken including um

approaches have been taken including um mandatory approaches so that we can

mandatory approaches so that we can learn what's worked and what hasn't

learn what's worked and what hasn't worked um and what might therefore be

worked um and what might therefore be likely to work or not work in the UK

likely to work or not work in the UK situation. So, it's an area that we're

situation. So, it's an area that we're we're very actively looking into so that

we're very actively looking into so that we can try and um keep that

we can try and um keep that collaboration but at the same time keep

collaboration but at the same time keep that drive um however that might look to

that drive um however that might look to get the data that we need to support the

get the data that we need to support the whole picture. Thanks.

whole picture. Thanks. >> Absolutely. Thank you very much. Um so

>> Absolutely. Thank you very much. Um so there's another question for you largely

there's another question for you largely Kitty around surveillance or AMR. So key

Kitty around surveillance or AMR. So key indicators for antimicrobial resistance

indicators for antimicrobial resistance show an overall really encouraging

show an overall really encouraging picture which was really nice to nice to

picture which was really nice to nice to see with the long-term trends showing

see with the long-term trends showing resistance is reducing which is a good

resistance is reducing which is a good news story. So, can the industry, can

news story. So, can the industry, can livestock producers celebrate now the

livestock producers celebrate now the fact that what they're doing is saving

fact that what they're doing is saving the lives of animals and people and that

the lives of animals and people and that we can confidently make this direct link

we can confidently make this direct link here between the work that's been going

here between the work that's been going on that we've seen showcased and the

on that we've seen showcased and the impact of what the science is telling

impact of what the science is telling us.

us. >> So, I mean, basically, I think yes, I I

>> So, I mean, basically, I think yes, I I think we can. I mean, it's I know we

think we can. I mean, it's I know we we're always slightly cy about it. I

we're always slightly cy about it. I mean, and we can't how can we prove it,

mean, and we can't how can we prove it, but the circumstantial evidence is all

but the circumstantial evidence is all over the results that we're seeing. And

over the results that we're seeing. And I think that the the work that the teams

I think that the the work that the teams um who in who've been generating and and

um who in who've been generating and and interpreting up the data on the clinical

interpreting up the data on the clinical surveillance this this year have as

surveillance this this year have as we've seen with the clinical

we've seen with the clinical surveillance ecoli um long-term trends

surveillance ecoli um long-term trends in different species um have shown I

in different species um have shown I mean that only adds to the to the

mean that only adds to the to the confidence that we have. So, I mean, um,

confidence that we have. So, I mean, um, I'm going to I'm going to speak from a

I'm going to I'm going to speak from a policy perspective, um, rather than a a

policy perspective, um, rather than a a pure science perspective, but yes, I

pure science perspective, but yes, I think everybody can be who's been

think everybody can be who's been involved can be can be really proud of,

involved can be can be really proud of, um, of of this and it's it's a fantastic

um, of of this and it's it's a fantastic outcome and trends to be really proud

outcome and trends to be really proud of.

of. >> Brilliant. Thank you so much, Kitty. I

>> Brilliant. Thank you so much, Kitty. I think that's a really nice note for us

think that's a really nice note for us to finish the Q&A on. I've just noticed

to finish the Q&A on. I've just noticed the time, so I'm afraid it's going to

the time, so I'm afraid it's going to I'm going to have to wrap us up now, but

I'm going to have to wrap us up now, but thank you both very much for your

thank you both very much for your presentations and um participation in

presentations and um participation in the Q&A.

the Q&A. So, um yeah, thank you. I want to thank

So, um yeah, thank you. I want to thank everyone who has taken part today to our

everyone who has taken part today to our speakers and to everyone who's attended

speakers and to everyone who's attended and those that have asked questions in

and those that have asked questions in the chat. I think we have actually

the chat. I think we have actually managed to answer all of those now,

managed to answer all of those now, which is great. Um, so both of these

which is great. Um, so both of these important industry reports demonstrate

important industry reports demonstrate another year of really great effort and

another year of really great effort and commitment from across the UK livestock

commitment from across the UK livestock sectors in the responsible use of

sectors in the responsible use of antibiotics. As we've heard, national

antibiotics. As we've heard, national usage figures remain stable and largely

usage figures remain stable and largely unchanged from last year and the

unchanged from last year and the long-term AMR surveillance work carried

long-term AMR surveillance work carried out by the VMD shows a really

out by the VMD shows a really encouraging picture. This is something

encouraging picture. This is something to be proud of and these latest results

to be proud of and these latest results should give everyone the ongoing

should give everyone the ongoing confidence and focus to build on what's

confidence and focus to build on what's already been done and to be ambitious

already been done and to be ambitious really and as ambitious as possible as

really and as ambitious as possible as we drive forward with efforts to

we drive forward with efforts to continue to tackle AMR and protect the

continue to tackle AMR and protect the efficacy of antibiotics because we all

efficacy of antibiotics because we all have this common goal of helping to save

have this common goal of helping to save the lives of animals and humans and it's

the lives of animals and humans and it's great to actually hear that we are doing

great to actually hear that we are doing that. Um so before we finish just a

that. Um so before we finish just a reminder that Rumor Agriculture will be

reminder that Rumor Agriculture will be launching the third cycle of the targets

launching the third cycle of the targets task force this time next week at

task force this time next week at another webinar. So please tune in this

another webinar. So please tune in this time next week. Um the details of how to

time next week. Um the details of how to book have been added to the meeting Q&A

book have been added to the meeting Q&A I believe and so Rumor Agriculture will

I believe and so Rumor Agriculture will also be sending out a booking link to

also be sending out a booking link to all of you who have attended today and

all of you who have attended today and we would love to see you the same time

we would love to see you the same time next week for that. Okay. So, I'm going

next week for that. Okay. So, I'm going to wrap us up now and um thank you

to wrap us up now and um thank you everyone for joining today's webinar and

everyone for joining today's webinar and we will see you next week.

Click on any text or timestamp to jump to that moment in the video

Most transcripts ready in under 5 seconds

One-Click Copy125+ LanguagesSearch ContentJump to Timestamps

Paste YouTube URL

Enter any YouTube video link to get the full transcript

Most transcripts ready in under 5 seconds

Get Our Chrome Extension

Get transcripts instantly without leaving YouTube. Install our Chrome extension for one-click access to any video's transcript directly on the watch page.

Add to Chrome — Free

Works with YouTube, Coursera, Udemy and more educational platforms

Get Instant Transcripts: Just Edit the Domain in Your Address Bar!

YouTube

←

→

↻

https://www.youtube.com/watch?v=UF8uR6Z6KLc

YoutubeToText

←

→

↻

https://youtubetotext.net/watch?v=UF8uR6Z6KLc

YouTube TranscriptPreparing your results…

YouTube Transcript:RUMA Agriculture Targets Task Force 2 FINAL Report and VARSS Report launch 2025